Aurinia Pharmaceuticals Inc. provided revenue guidance for the year 2022 and 2023. Given these current market dynamics, company is adjusting net revenue guidance to $100 million - $105 million from sales of LUPKYNIS for 2022. Company is also providing preliminary net revenue guidance from product sales of LUPKYNIS for 2023 in the range of $120-140 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.205 USD | -1.61% | -6.78% | -42.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.66% | 755M | |
+8.75% | 115B | |
+9.42% | 105B | |
-12.97% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.92% | 16.52B | |
-16.35% | 16.01B | |
+1.68% | 14.14B | |
+17.21% | 10.71B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022 and 2023